Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial

PURPOSE: Patients with platinum-resistant ovarian cancer respond poorly to existing therapies. Hence there is a need for more effective treatments. PATIENTS AND METHODS: The DeCidE(1) trial is a multicenter, randomized, open-label, single-arm phase II study to evaluate the safety and effectiveness o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorigo, Oliver, Oza, Amit M., Pejovic, Tanja, Ghatage, Prafull, Ghamande, Sharad, Provencher, Diane, MacDonald, Lisa D., Torrey, Heather, Kaliaperumal, Valarmathy, Ebrahimizadeh, Walead, Hirsch, Heather A., Bramhecha, Yogesh, Villella, Jeannine, Fiset, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390884/
https://www.ncbi.nlm.nih.gov/pubmed/37126016
http://dx.doi.org/10.1158/1078-0432.CCR-22-2595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390884/
https://www.ncbi.nlm.nih.gov/pubmed/37126016
http://dx.doi.org/10.1158/1078-0432.CCR-22-2595

Ejemplares similares